Company Filing History:
1 out of 517 
1 out of 5 Years Active: 2010-2012
Title: Ralph Pannell: Innovator in Fibrinolysis Research
Introduction
Ralph Pannell is a notable inventor based in Brighton, MA (US), recognized for his contributions to the field of fibrinolysis. He holds 2 patents that focus on improving the safety and efficacy of fibrinolytic therapies. His innovative work has significant implications for medical treatments related to blood clotting.
Latest Patents
Pannell's latest patents include a groundbreaking invention involving a C1-inhibitor that prevents non-specific plasminogen activation by a prourokinase mutant. This mutant prourokinase plasminogen activator, referred to as M5, was developed to reduce spontaneous activation during fibrinolysis. The C1-inhibitor complexes with tcM5, and its effects on fibrinolysis and fibrinogenolysis by M5 were thoroughly investigated. The findings revealed that supplemental C1-inhibitor restores the stability of M5 without affecting prouPA. Clot lysis by M5 with supplemental C1-inhibitor demonstrated no reduction in the rate of fibrinolysis, while fibrinogenolysis was effectively prevented. The higher dose tolerance of M5 with C1-inhibitor allowed for a rate of fibrin-specific lysis comparable to that achieved by nonspecific fibrinolysis without an inhibitor. This unique dissociation of effects has important implications for enhancing the safety and efficacy of fibrinolysis.
Career Highlights
Throughout his career, Ralph Pannell has worked with esteemed organizations such as Beth Israel Deaconess Medical Center and Thrombolytic Science, LLC. His research has contributed to advancements in the understanding and treatment of conditions related to blood clotting and fibrinolysis.
Collaborations
Pannell has collaborated with notable professionals in his field, including Victor Gurewich, to further his research and innovations.
Conclusion
Ralph Pannell's work in fibrinolysis research exemplifies the impact of innovative thinking in medical science. His patents and collaborations continue to pave the way for advancements in treatment methodologies.